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    In our department， 1 1 patients with prostatic carcinoma were treatecl with peplomycin， a derivative
ofbleomycin， They were aged from 62 to 84， and clinically classified （by the Whitemore classification）
to 1 in stage A， 3 in stage B， 3 in stage C and 4 in stage D．
    Peplomycin was administered on the dosage schedule of 5 or 10 mg at a time， 3 times a week，
to the target total dose of 180 mg． The effects of this drug against prostatic carcinoma were evaluated
in terms of （1） changes in the size of the prostate， those in acid phosphatase activity and the trend
of bone metastasis，（2）histopathologica1丘ndings after the treatment， and（3）Iong－term survival．
The adverse reactions to the treatment were also studied．
    The patients received peplomycin to the total doses of 80 to 190 rng （135 mg on the average）．
The drug was withdrawn from 5 of them for adverse reactions．
    At the end of the treatment， the prostate was found to have been reduced in size in 7， and un－
changed in 3 of them． Acid phosphatase activity， which had been elevated in 5， was normal in all
the 5 patients． Bone metastases had been noted in 4 of the 11 patients， but the clinical symptom
（pain） had disappeared from all the 4 patients．
    The pDsttreatment histopathological findings of the prostate tissue specimens obtained by TUR
were grade Ila in 1， grade Ilb in 3， grade III in 4 and grade IVa in 3 ofthe patients by the Shimosato
classification．
    Excluding 1 patient who died of an unknown cause 6 months after the end of the treatment and
another of cerebral hemorrhage 7 months after the treatment， recurrence was noted 12 months after
the treatment in one of the remaining 9 patients， while the other 8 have remained without any sign
of recurrence for 2 to 25 months．
    The adverse reactions noted during the treatment consisted of dermatitis in 3 and interstitial
pneumonitis in 5 patients； and the treatment was withdrawn from 5 of them． The interstitial pneu－
monitis was noted in the elderly patients aged 78 or more．
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分 化  80mg
分化180mg
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量は80mg～130 mg，平均106 mgでGIIa l例，
GIIb 2例， GIH 1例であり，他の6例はペプロマイ
シン総投与量が1501ng～190 mg，平均177 mgで
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例 ．ペプロマイシン酷蒲^量 3 6 9 12
ペプロマイシン投与終了後月数
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